{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:19:55Z","timestamp":1791836395704,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1177\/2168479017716713","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T08:27:44Z","timestamp":1498638464000},"page":"100-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neonatal Safety Information Reported to the FDA During Drug Development Studies"],"prefix":"10.1007","volume":"52","author":[{"given":"Debbie","family":"Avant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerri","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Sorbello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Ariagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert J.","family":"Burckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,30]]},"reference":[{"key":"5201100_CR1","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.285.16.2114","volume":"285","author":"R Kaushal","year":"2001","unstructured":"Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285:2114\u20132120.","journal-title":"JAMA"},{"key":"5201100_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00148581-200911020-00005","volume":"11","author":"DL Kunac","year":"2009","unstructured":"Kunac DL, Kennedy J, Austin N, Reith D. Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study. Paediatr Drugs. 2009;11:153\u2013160.","journal-title":"Paediatr Drugs"},{"key":"5201100_CR3","unstructured":"General Clinical Pharmacology Considerations for Pediatric Studies for drugs and Biological Products: Guidance for Industry (Draft). Rockville, MD: Center for Drug Evaluation and Research (CDER), Food and Drug Administration, US Department of Health and Human Services; 2014."},{"key":"5201100_CR4","unstructured":"21 CFR \u00a7314.80."},{"key":"5201100_CR5","unstructured":"21 CFR \u00a7201.57."},{"key":"5201100_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jpeds.2007.07.050","volume":"152","author":"P Kumar","year":"2008","unstructured":"Kumar P, Walker JK, Hurt KM, Bennett KM, Grosshans N, Fotis MA. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications. J Pediatr. 2008;152:412\u2013415.","journal-title":"J Pediatr"},{"key":"5201100_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1055\/s-0033-1361933","volume":"31","author":"EM Hsieh","year":"2014","unstructured":"Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr., Smith PB. Medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31:811\u2013821.","journal-title":"Am J Perinatol"},{"key":"5201100_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/14740338.5.5.703","volume":"5","author":"L Cuzzolin","year":"2006","unstructured":"Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5:703\u2013718.","journal-title":"Expert Opin Drug Saf"},{"key":"5201100_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1046\/j.1365-2125.2002.t01-3-01689.x","volume":"54","author":"B Horen","year":"2002","unstructured":"Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665\u2013670.","journal-title":"Br J Clin Pharmacol"},{"key":"5201100_CR10","unstructured":"Food and Drug Administration Safety and Innovation Act, S. 3187-3 (2012)."},{"key":"5201100_CR11","unstructured":"Best Pharmaceuticals for Children Act, 115 Stat 1408, 21 USC 355a (2002)."},{"key":"5201100_CR12","unstructured":"Pediatric Research Equity Act of 2003, S 650, 108th Cong (2003). http:\/\/frwebgate.access.gpo.gov\/cgi-bin\/getdoc.cgi?dbname=108_cong_bills&docid=f:s650enr.txt."},{"key":"5201100_CR13","unstructured":"21 CFR \u00a7314.108(a)."},{"key":"5201100_CR14","unstructured":"New Pediatric Labeling Database. http:\/\/www.accessdata.fda.gov\/scripts\/sda\/sdNavigation.cfm?sd=labelingdatabase. Accessed December 31, 2015."},{"key":"5201100_CR15","unstructured":"Food and Drug Administration Amendments Act, 21 USC 301, \u00a7505A, 505B (2007)."},{"key":"5201100_CR16","unstructured":"Drugs@FDA: FDA approved drug products. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm. Published 2015."},{"key":"5201100_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamapediatrics.2013.4208","volume":"168","author":"MM Laughon","year":"2014","unstructured":"Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168:130\u2013136.","journal-title":"JAMA Pediatr"},{"key":"5201100_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-011-1183-4","volume":"68","author":"AN Rashed","year":"2012","unstructured":"Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2012;68:801\u2013810.","journal-title":"Eur J Clin Pharmacol"},{"key":"5201100_CR19","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","volume":"98","author":"JA Berlin","year":"2008","unstructured":"Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98:1366\u20131371.","journal-title":"Am J Public Health"},{"key":"5201100_CR20","first-page":"261","volume":"92","author":"MS Tassinari","year":"2011","unstructured":"Tassinari MS, Benson K, Elayan I, Espandiari P, Davis-Bruno K. Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling. Birth Defects Res B Dev Reprod Toxicol. 2011;92:261\u2013265.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"5201100_CR21","unstructured":"Guidance for Industry: Nonclinical Safety Evaluation of Pediatric Drug Products. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm079247.pdf. Published 2006."},{"key":"5201100_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1056\/NEJMoa061088","volume":"355","author":"RA Ballard","year":"2006","unstructured":"Ballard RA, Truog WE, Cnaan A, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355:343\u2013353.","journal-title":"N Engl J Med"},{"key":"5201100_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa060442","volume":"355","author":"JP Kinsella","year":"2006","unstructured":"Kinsella JP, Cutter GR, Walsh WF, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006;355:354\u2013364.","journal-title":"N Engl J Med"},{"key":"5201100_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S0140-6736(10)60664-2","volume":"376","author":"JC Mercier","year":"2010","unstructured":"Mercier JC, Hummler H, Durrmeyer X, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376:346\u2013354.","journal-title":"Lancet"},{"key":"5201100_CR25","unstructured":"Food and Drug Administration. MedWatch. http:\/\/www.fda.gov\/medwatch\/index.html."},{"key":"5201100_CR26","unstructured":"FDA Drug Safety Communication: Serious health problems seen in premature babies given Kaletra (lopinavir\/ritonavir) oral solution. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm246002.htm#safety_announcement. Published 2011."},{"key":"5201100_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3109\/03639045.2013.850713","volume":"40","author":"AA Ali","year":"2014","unstructured":"Ali AA, Charoo NA, Abdallah DB. Pediatric drug development: formulation considerations. Drug Dev Ind Pharm. 2014;40:1283\u20131299.","journal-title":"Drug Dev Ind Pharm"},{"key":"5201100_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fped.2014.00135","volume":"2","author":"SK McCune","year":"2014","unstructured":"McCune SK, Mulugeta YA. Regulatory science needs for neonates: a call for neonatal community collaboration and innovation. Front Pediatr. 2014;2:135.","journal-title":"Front Pediatr"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479017716713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2168479017716713","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1177\/2168479017716713\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2168479017716713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479017716713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T13:04:24Z","timestamp":1598015064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1177\/2168479017716713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["5201100"],"URL":"https:\/\/doi.org\/10.1177\/2168479017716713","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"8 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}